Rhumbline Advisers Alkermes Plc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Alkermes Plc. stock. As of the latest transaction made, Rhumbline Advisers holds 463,031 shares of ALKS stock, worth $13.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
463,031
Previous 497,313 6.89%
Holding current value
$13.6 Million
Previous $12 Million 8.14%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$23.01 - $28.55 $788,828 - $978,751
-34,282 Reduced 6.89%
463,031 $13 Million
Q2 2024

Aug 01, 2024
BUY
$23.21 - $27.24 $179,227 - $210,347
7,722 Added 1.58%
497,313 $12 Million
Q1 2024

May 09, 2024
BUY
$26.4 - $32.56 $96,439 - $118,941
3,653 Added 0.75%
489,591 $13.3 Million
Q4 2023

Feb 08, 2024
BUY
$23.37 - $28.68 $5.79 Million - $7.11 Million
247,802 Added 104.06%
485,938 $13.5 Million
Q3 2023

Nov 09, 2023
BUY
$27.17 - $31.97 $111,342 - $131,013
4,098 Added 1.75%
238,136 $6.67 Million
Q2 2023

Aug 08, 2023
BUY
$28.34 - $33.63 $134,700 - $159,843
4,753 Added 2.07%
234,038 $7.33 Million
Q1 2023

May 11, 2023
BUY
$25.31 - $29.02 $31,586 - $36,216
1,248 Added 0.55%
229,285 $6.46 Million
Q4 2022

Feb 14, 2023
BUY
$21.94 - $26.24 $257,092 - $307,480
11,718 Added 5.42%
228,037 $5.96 Million
Q3 2022

Nov 10, 2022
BUY
$22.0 - $31.87 $346,632 - $502,143
15,756 Added 7.86%
216,319 $4.83 Million
Q2 2022

Aug 11, 2022
BUY
$26.4 - $30.54 $738,328 - $854,112
27,967 Added 16.2%
200,563 $5.98 Million
Q1 2022

May 12, 2022
BUY
$23.07 - $27.99 $208,091 - $252,469
9,020 Added 5.51%
172,596 $4.54 Million
Q4 2021

Feb 10, 2022
SELL
$21.47 - $32.08 $44,442 - $66,405
-2,070 Reduced 1.25%
163,576 $3.81 Million
Q3 2021

Nov 12, 2021
BUY
$23.37 - $32.13 $70,296 - $96,647
3,008 Added 1.85%
165,646 $5.11 Million
Q2 2021

Aug 05, 2021
SELL
$18.78 - $25.15 $21,277 - $28,494
-1,133 Reduced 0.69%
162,638 $3.99 Million
Q1 2021

May 06, 2021
SELL
$18.21 - $23.2 $147,592 - $188,036
-8,105 Reduced 4.72%
163,771 $3.06 Million
Q4 2020

Feb 10, 2021
BUY
$15.39 - $22.1 $105,652 - $151,716
6,865 Added 4.16%
171,876 $3.43 Million
Q3 2020

Nov 12, 2020
SELL
$16.16 - $20.66 $72,041 - $92,102
-4,458 Reduced 2.63%
165,011 $2.73 Million
Q2 2020

Aug 13, 2020
BUY
$13.31 - $19.41 $123,104 - $179,523
9,249 Added 5.77%
169,469 $3.29 Million
Q1 2020

May 06, 2020
BUY
$13.06 - $21.24 $483,233 - $785,901
37,001 Added 30.03%
160,220 $2.31 Million
Q4 2019

Feb 05, 2020
BUY
$17.29 - $21.74 $27,162 - $34,153
1,571 Added 1.29%
123,219 $2.51 Million
Q3 2019

Oct 23, 2019
BUY
$19.51 - $24.28 $41,166 - $51,230
2,110 Added 1.77%
121,648 $2.37 Million
Q2 2019

Aug 14, 2019
SELL
$21.47 - $37.33 $645,323 - $1.12 Million
-30,057 Reduced 20.09%
119,538 $2.69 Million
Q1 2019

May 01, 2019
SELL
$28.4 - $36.49 $21,072 - $27,075
-742 Reduced 0.49%
149,595 $5.46 Million
Q4 2018

Jan 31, 2019
SELL
$27.94 - $44.61 $260,959 - $416,657
-9,340 Reduced 5.85%
150,337 $4.44 Million
Q3 2018

Nov 07, 2018
SELL
$38.6 - $46.12 $157,488 - $188,169
-4,080 Reduced 2.49%
159,677 $6.78 Million
Q2 2018

Aug 06, 2018
BUY
$40.56 - $51.36 $131,252 - $166,200
3,236 Added 2.02%
163,757 $6.74 Million
Q1 2018

May 02, 2018
SELL
$53.61 - $67.26 $300,055 - $376,454
-5,597 Reduced 3.37%
160,521 $9.3 Million
Q4 2017

Feb 09, 2018
SELL
$47.69 - $55.39 $287,189 - $333,558
-6,022 Reduced 3.5%
166,118 $9.09 Million
Q3 2017

Nov 06, 2017
BUY
$49.16 - $54.45 $8.46 Million - $9.37 Million
172,140
172,140 $8.75 Million

Others Institutions Holding ALKS

# of Institutions
361
Shares Held
181M
Call Options Held
175K
Put Options Held
96.6K
View Full List

About Alkermes plc.

ALKS Quotes by TradingView
  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.84B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email